Antinuclear antibodies as ancillary markers in primary biliary cirrhosis

References

• Kaplan MM, Gershwin ME. Primary biliary cirrhosis. N. Engl. J. Med.353(12), 1261–1273 (2005).
   PubMed Web of Science ®Google Scholar
• Muratori L, Granito A, Muratori P, Pappas G, Bianchi FB. Antimitochondrial antibodies and other antibodies in primary biliary cirrhosis: diagnostic and prognostic value. Clin. Liver Dis.12(2), 261–276 vii (2008).
   PubMed Web of Science ®Google Scholar
• Bogdanos DP, Komorowski L. Disease-specific autoantibodies in primary biliary cirrhosis. Clin. Chim. Acta412(7–8), 502–512 (2011).
   PubMed Web of Science ®Google Scholar
• Remmel T, Piirsoo A, Koiveer A, Remmel H, Uibo R, Salupere V. Clinical significance of different antinuclear antibodies patterns in the course of primary biliary cirrhosis. Hepatogastroenterology43(11), 1135–1140 (1996).
   PubMed Web of Science ®Google Scholar
• Marasini B, Gagetta M, Rossi V, Ferrari P. Rheumatic disorders and primary biliary cirrhosis: an appraisal of 170 Italian patients. Ann. Rheum. Dis.60(11), 1046–1049 (2001).
   PubMed Web of Science ®Google Scholar
• Muratori P, Muratori L, Ferrari R et al. Characterization and clinical impact of antinuclear antibodies in primary biliary cirrhosis. Am. J. Gastroenterol.98(2), 431–437 (2003).
   PubMed Web of Science ®Google Scholar
• Yang WH, Yu JH, Nakajima A, Neuberg D, Lindor K, Bloch DB. Do antinuclear antibodies in primary biliary cirrhosis patients identify increased risk for liver failure? Clin. Gastroenterol. Hepatol.2(12), 1116–1122 (2004).
   PubMed Web of Science ®Google Scholar
• Rigopoulou EI, Davies ET, Pares A et al. Prevalence and clinical significance of isotype specific antinuclear antibodies in primary biliary cirrhosis. Gut54(4), 528–532 (2005).
   PubMed Web of Science ®Google Scholar
• Walker JG, Doniach D, Roitt IM, Sherlock S. Serological tests in diagnosis of primary biliary cirrhosis. Lancet1(7390), 827–831 (1965).
   PubMed Web of Science ®Google Scholar
• Doniach D, Roitt IM, Walker JG, Sherlock S. Tissue antibodies in primary biliary cirrhosis, active chronic (lupoid) hepatitis, cryptogenic cirrhosis and other liver diseases and their clinical implications. Clin. Exp. Immunol.1(3), 237–262 (1966).
   PubMedGoogle Scholar
• Parveen S, Morshed SA, Nishioka M. High prevalence of antibodies to recombinant CENP-B in primary biliary cirrhosis: nuclear immunofluorescence patterns and ELISA reactivities. J. Gastroenterol. Hepatol.10(4), 438–445 (1995).
   PubMed Web of Science ®Google Scholar
• Rigamonti C, Shand LM, Feudjo M et al. Clinical features and prognosis of primary biliary cirrhosis associated with systemic sclerosis. Gut55(3), 388–394 (2006).
   PubMed Web of Science ®Google Scholar
• Granito A, Muratori P, Muratori L et al. Antibodies to SS-A/Ro-52kD and centromere in autoimmune liver disease: a clue to diagnosis and prognosis of primary biliary cirrhosis. Aliment Pharmacol. Ther.26(6), 831–838 (2007).
   PubMed Web of Science ®Google Scholar
• Chou MJ, Lee SL, Chen TY, Tsay GJ. Specificity of antinuclear antibodies in primary biliary cirrhosis. Ann. Rheum. Dis.54(2), 148–151 (1995).
   PubMedGoogle Scholar
• Agmon-Levin N, Shapira Y, Selmi C et al. A comprehensive evaluation of serum autoantibodies in primary biliary cirrhosis. J. Autoimmun.34(1), 55–58 (2010).
   PubMed Web of Science ®Google Scholar
• Invernizzi P, Selmi C, Ranftler C, Podda M, Wesierska-Gadek J. Antinuclear antibodies in primary biliary cirrhosis. Semin. Liver Dis.25(3), 298–310 (2005).
   PubMed Web of Science ®Google Scholar
• Invernizzi P, Podda M, Battezzati PM et al. Autoantibodies against nuclear pore complexes are associated with more active and severe liver disease in primary biliary cirrhosis. J. Hepatol.34(3), 366–372 (2001).
   PubMed Web of Science ®Google Scholar
• Szostecki C, Guldner HH, Will H. Autoantibodies against ‘nuclear dots’ in primary biliary cirrhosis. Semin. Liver Dis.17(1), 71–78 (1997).
   PubMed Web of Science ®Google Scholar
• Borden KL. Pondering the promyelocytic leukemia protein (PML) puzzle: possible functions for PML nuclear bodies. Mol. Cell Biol.22(15), 5259–5269 (2002).
   PubMedGoogle Scholar
• Worman HJ, Courvalin JC. Antinuclear antibodies specific for primary biliary cirrhosis. Autoimmun. Rev.2(4), 211–217 (2003).
   PubMed Web of Science ®Google Scholar
• Janka C, Selmi C, Gershwin ME, Will H, Sternsdorf T. Small ubiquitin-related modifiers: a novel and independent class of autoantigens in primary biliary cirrhosis. Hepatology41(3), 609–616 (2005).
   PubMed Web of Science ®Google Scholar
• Granito A, Yang WH, Muratori L et al. PML nuclear body component Sp140 is a novel autoantigen in primary biliary cirrhosis. Am. J. Gastroenterol.105(1), 125–131 (2010).
   PubMed Web of Science ®Google Scholar
• Szostecki C, Krippner H, Penner E, Bautz FA. Autoimmune sera recognize a 100 kD nuclear protein antigen (sp-100). Clin. Exp. Immunol.68(1), 108–116 (1987).
   PubMed Web of Science ®Google Scholar
• Szostecki C, Guldner HH, Netter HJ, Will H. Isolation and characterization of cDNA encoding a human nuclear antigen predominantly recognized by autoantibodies from patients with primary biliary cirrhosis. J. Immunol.145(12), 4338–4347 (1990).
   PubMed Web of Science ®Google Scholar
• Bluthner M, Schafer C, Schneider C, Bautz FA. Identification of major linear epitopes on the sp100 nuclear PBC autoantigen by the gene-fragment phage-display technology. Autoimmunity29(1), 33–42 (1999).
   PubMed Web of Science ®Google Scholar
• Powell F, Schroeter AL, Dickson ER. Antinuclear antibodies in primary biliary cirrhosis. Lancet1(8371), 288–289 (1984).
   PubMed Web of Science ®Google Scholar
• Zuchner D, Sternsdorf T, Szostecki C, Heathcote EJ, Cauch-Dudek K, Will H. Prevalence, kinetics, and therapeutic modulation of autoantibodies against Sp100 and promyelocytic leukemia protein in a large cohort of patients with primary biliary cirrhosis. Hepatology26(5), 1123–1130 (1997).
   PubMed Web of Science ®Google Scholar
• Muratori P, Muratori L, Cassani F et al. Anti-multiple nuclear dots (anti-MND) and anti-SP100 antibodies in hepatic and rheumatological disorders. Clin. Exp. Immunol.127(1), 172–175 (2002).
   PubMed Web of Science ®Google Scholar
• Dubel L, Farges O, Courvalin JC, Sebagh M, Johanet C. Persistence of gp210 and multiple nuclear dots antibodies does not correlate with recurrence of primary biliary cirrhosis 6 years after liver transplantation. J. Hepatol.28(1), 169–170 (1998).
   PubMedGoogle Scholar
• Luettig B, Boeker KH, Schoessler W et al. The antinuclear autoantibodies Sp100 and gp210 persist after orthotopic liver transplantation in patients with primary biliary cirrhosis. J. Hepatol.28(5), 824–828 (1998).
   PubMed Web of Science ®Google Scholar
• Vergani D, Bogdanos DP. Positive markers in AMA-negative PBC. Am. J. Gastroenterol.98(2), 241–243 (2003).
   PubMed Web of Science ®Google Scholar
• Pawlotsky JM, Andre C, Metreau JM, Beaugrand M, Zafrani ES, Dhumeaux D. Multiple nuclear dots antinuclear antibodies are not specific for primary biliary cirrhosis. Hepatology16(1), 127–131 (1992).
   PubMedGoogle Scholar
• Wichmann I, Montes-Cano MA, Respaldiza N et al. Clinical significance of anti-multiple nuclear dots/Sp100 autoantibodies. Scand. J. Gastroenterol.38(9), 996–999 (2003).
   PubMed Web of Science ®Google Scholar
• Bogdanos DP, Vergani D, Muratori P, Muratori L, Bianchi FB. Specificity of anti-sp100 antibody for primary biliary cirrhosis. Scand. J. Gastroenterol.39(4), 405–406 author reply 407 (2004).
   PubMed Web of Science ®Google Scholar
• Rigopoulou EI, Dalekos GN. Anti-sp100 antibodies in primary biliary cirrhosis. Scand. J. Gastroenterol.39(4), 406–407; author reply 407 (2004).
   PubMed Web of Science ®Google Scholar
• Granito A, Muratori P, Muratori L et al. Antinuclear antibodies giving the ‘multiple nuclear dots’ or the ‘rim-like/membranous’ patterns: diagnostic accuracy for primary biliary cirrhosis. Aliment Pharmacol. Ther.24(11–12), 1575–1583 (2006).
   PubMedGoogle Scholar
• De Thé H, Chomienne C, Lanotte M, Degos L, Dejean A. The t(15;17) translocation of acute promyelocytic leukaemia fuses the retinoic acid receptor α gene to a novel transcribed locus. Nature347(6293), 558–561 (1990).
   PubMed Web of Science ®Google Scholar
• Sternsdorf T, Grotzinger T, Jensen K, Will H. Nuclear dots: actors on many stages. Immunobiology198(1–3), 307–331 (1997).
   PubMedGoogle Scholar
• Sternsdorf T, Guldner HH, Szostecki C, Grotzinger T, Will H. Two nuclear dot-associated proteins, PML and Sp100, are often co-autoimmunogenic in patients with primary biliary cirrhosis. Scand. J. Immunol.42(2), 257–268 (1995).
   PubMed Web of Science ®Google Scholar
• Ruffatti A, Arslan P, Floreani A et al. Nuclear membrane-staining antinuclear antibody in patients with primary biliary cirrhosis. J. Clin. Immunol.5(5), 357–361 (1985).
   PubMed Web of Science ®Google Scholar
• Ye Q, Worman HJ. Primary structure analysis and lamin B and DNA binding of human LBR, an integral protein of the nuclear envelope inner membrane. J. Biol. Chem.269(15), 11306–11311 (1994).
   PubMed Web of Science ®Google Scholar
• Worman HJ, Lazaridis I, Georgatos SD. Nuclear lamina heterogeneity in mammalian cells. Differential expression of the major lamins and variations in lamin B phosphorylation. J. Biol. Chem.263(24), 12135–12141 (1988).
   PubMedGoogle Scholar
• Wesierska-Gadek J, Hohenuer H, Hitchman E, Penner E. Autoantibodies against nucleoporin p62 constitute a novel marker of primary biliary cirrhosis. Gastroenterology110(3), 840–847 (1996).
   PubMed Web of Science ®Google Scholar
• Reeves WH, Chaudhary N, Salerno A, Blobel G. Lamin B autoantibodies in sera of certain patients with systemic lupus erythematosus. J. Exp. Med.165(3), 750–762 (1987).
   PubMedGoogle Scholar
• Lassoued K, Brenard R, Degos F et al. Antinuclear antibodies directed to a 200-kilodalton polypeptide of the nuclear envelope in primary biliary cirrhosis. A clinical and immunological study of a series of 150 patients with primary biliary cirrhosis. Gastroenterology99(1), 181–186 (1990).
   PubMed Web of Science ®Google Scholar
• Senecal JL, Ichiki S, Girard D, Raymond Y. Autoantibodies to nuclear lamins and to intermediate filament proteins: natural, pathologic or pathogenic? J. Rheumatol.20(2), 211–219 (1993).
   PubMedGoogle Scholar
• Konstantinov K, Foisner R, Byrd D et al. Integral membrane proteins associated with the nuclear lamina are novel autoimmune antigens of the nuclear envelope. Clin. Immunol. Immunopathol.74(1), 89–99 (1995).
   PubMedGoogle Scholar
• Bandin O, Courvalin JC, Poupon R, Dubel L, Homberg JC, Johanet C. Specificity and sensitivity of gp210 autoantibodies detected using an enzyme-linked immunosorbent assay and a synthetic polypeptide in the diagnosis of primary biliary cirrhosis. Hepatology23(5), 1020–1024 (1996).
   PubMedGoogle Scholar
• Miyachi K, Shibata M, Onozuka Y, Kikuchi F, Imai N, Horigome T. Primary biliary cirrhosis sera recognize not only gp210 but also proteins of the p62 complex bearing N-acetylglucosamine residues from rat liver nuclear envelope. Anti-p62 complex antibody in PBC. Mol. Biol. Rep.23(3–4), 227–234 (1996).
   PubMed Web of Science ®Google Scholar
• Lozano F, Pares A, Borche L et al. Autoantibodies against nuclear envelope-associated proteins in primary biliary cirrhosis. Hepatology8(4), 930–938 (1988).
   PubMed Web of Science ®Google Scholar
• Lassoued K, Guilly MN, Andre C et al. Autoantibodies to 200 kD polypeptide(s) of the nuclear envelope: a new serologic marker of primary biliary cirrhosis. Clin. Exp. Immunol.74(2), 283–288 (1988).
   PubMed Web of Science ®Google Scholar
• Courvalin JC, Lassoued K, Bartnik E, Blobel G, Wozniak RW. The 210-kD nuclear envelope polypeptide recognized by human autoantibodies in primary biliary cirrhosis is the major glycoprotein of the nuclear pore. J. Clin. Invest.86(1), 279–285 (1990).
   PubMed Web of Science ®Google Scholar
• Nickowitz RE, Worman HJ. Autoantibodies from patients with primary biliary cirrhosis recognize a restricted region within the cytoplasmic tail of nuclear pore membrane glycoprotein Gp210. J. Exp. Med.178(6), 2237–2242 (1993).
   PubMed Web of Science ®Google Scholar
• Wesierska-Gadek J, Hohenauer H, Hitchman E, Penner E. Autoantibodies from patients with primary biliary cirrhosis preferentially react with the amino-terminal domain of nuclear pore complex glycoprotein gp210. J. Exp. Med.182(4), 1159–1162 (1995).
   PubMed Web of Science ®Google Scholar
• Wesierska-Gadek J, Hohenauer H, Hitchman E, Penner E. Autoantibodies against constituents of nuclear pore complexes in patients with primary biliary cirrhosis and autoimmune hepatitis. Acta Biochim. Pol.42(2), 197–200 (1995).
   PubMedGoogle Scholar
• Wesierska-Gadek J, Hohenauer H, Hitchman E, Penner E. Anti-gp210 antibodies in sera of patients with primary biliary cirrhosis. Identification of a 64 kD fragment of gp210 as a major epitope. Hum. Antibodies Hybridomas7(4), 167–174 (1996).
   PubMedGoogle Scholar
• Nickowitz RE, Wozniak RW, Schaffner F, Worman HJ. Autoantibodies against integral membrane proteins of the nuclear envelope in patients with primary biliary cirrhosis. Gastroenterology106(1), 193–199 (1994).
   PubMed Web of Science ®Google Scholar
• Itoh S, Ichida T, Yoshida T et al. Autoantibodies against a 210 kDa glycoprotein of the nuclear pore complex as a prognostic marker in patients with primary biliary cirrhosis. J. Gastroenterol. Hepatol.13(3), 257–265 (1998).
   PubMed Web of Science ®Google Scholar
• Miyachi K, Hankins RW, Matsushima H et al. Profile and clinical significance of anti-nuclear envelope antibodies found in patients with primary biliary cirrhosis: a multicenter study. J. Autoimmun.20(3), 247–254 (2003).
   PubMed Web of Science ®Google Scholar
• Wesierska-Gadek J, Penner E, Battezzati PM et al. Correlation of initial autoantibody profile and clinical outcome in primary biliary cirrhosis. Hepatology43(5), 1135–1144 (2006).
   PubMed Web of Science ®Google Scholar
• Courvalin JC, Lassoued K, Worman HJ, Blobel G. Identification and characterization of autoantibodies against the nuclear envelope lamin B receptor from patients with primary biliary cirrhosis. J. Exp. Med.172(3), 961–967 (1990).
   PubMed Web of Science ®Google Scholar
• Worman HJ, Yuan J, Blobel G, Georgatos SD. A lamin B receptor in the nuclear envelope. Proc. Natl Acad. Sci. USA85(22), 8531–8534 (1988).
   PubMed Web of Science ®Google Scholar
• Lin F, Noyer CM, Ye Q, Courvalin JC, Worman HJ. Autoantibodies from patients with primary biliary cirrhosis recognize a region within the nucleoplasmic domain of inner nuclear membrane protein LBR. Hepatology23(1), 57–61 (1996).
   PubMed Web of Science ®Google Scholar
• Orton SM, Peace-Brewer A, Schmitz JL, Freeman K, Miller WC, Folds JD. Practical evaluation of methods for detection and specificity of autoantibodies to extractable nuclear antigens. Clin. Diagn. Lab Immunol.11(2), 297–301 (2004).
   PubMedGoogle Scholar
• Briolay J, Gioud M, Monier JC et al. Antinuclear antibodies detected by indirect immunofluorescence on HEp2 cells and by immunoblotting in patients with systemic sclerosis. Autoimmunity2(2), 165–176 (1989).
   PubMed Web of Science ®Google Scholar
• Eissfeller P, Sticherling M, Scholz D et al. Comparison of different test systems for simultaneous autoantibody detection in connective tissue diseases. Ann. NY Acad. Sci.1050, 327–339 (2005).
   PubMedGoogle Scholar
• Muratori P, Granito A, Pappas G et al. The serological profile of the autoimmune hepatitis/primary biliary cirrhosis overlap syndrome. Am. J. Gastroenterol.104(6), 1420–1425 (2009).
   PubMed Web of Science ®Google Scholar
• Efe C, Purnak T, Ozaslan E, Wahlin S. The serological profile of the autoimmune hepatitis/primary biliary cirrhosis overlap syndrome. Am. J. Gastroenterol.105(1), 226, author reply 226–227 (2010).
   PubMedGoogle Scholar
• Prince M, Chetwynd A, Newman W, Metcalf JV, James OF. Survival and symptom progression in a geographically based cohort of patients with primary biliary cirrhosis: follow-up for up to 28 years. Gastroenterology123(4), 1044–1051 (2002).
   PubMed Web of Science ®Google Scholar
• Springer J, Cauch-Dudek K, O’Rourke K, Wanless IR, Heathcote EJ. Asymptomatic primary biliary cirrhosis: a study of its natural history and prognosis. Am. J. Gastroenterol.94(1), 47–53 (1999).
   PubMed Web of Science ®Google Scholar
• Nakamura M, Shimizu-Yoshida Y, Takii Y et al. Antibody titer to gp210-C terminal peptide as a clinical parameter for monitoring primary biliary cirrhosis. J. Hepatol.42(3), 386–392 (2005).
   PubMed Web of Science ®Google Scholar
• Nakamura M, Kondo H, Mori T et al. Anti-gp210 and anti-centromere antibodies are different risk factors for the progression of primary biliary cirrhosis. Hepatology45(1), 118–127 (2007).
   PubMed Web of Science ®Google Scholar
• Bogdanos DP, Liaskos C, Pares A et al. Anti-gp210 antibody mirrors disease severity in primary biliary cirrhosis. Hepatology45(6), 1583; author reply 1583–1584 (2007).
   PubMed Web of Science ®Google Scholar
• Sfakianaki O, Koulentaki M, Tzardi M et al. Peri-nuclear antibodies correlate with survival in Greek primary biliary cirrhosis patients. World J. Gastroenterol.16(39), 4938–4943 (2010).
   PubMed Web of Science ®Google Scholar
• Vergani D, Alvarez F, Bianchi FB et al. Liver autoimmune serology: a consensus statement from the committee for autoimmune serology of the International autoimmune hepatitis group. J. Hepatol.41(4), 677–683 (2004).
   PubMed Web of Science ®Google Scholar
• Rigopoulou EI, Dalekos GN. Molecular diagnostics of primary biliary cirrhosis. Expert Opin. Med. Diagn.2(6), 621–634 (2008).
   PubMedGoogle Scholar
• Liu H, Norman GL, Shums Z et al. PBC screen: an IgG/IgA dual isotype ELISA detecting multiple mitochondrial and nuclear autoantibodies specific for primary biliary cirrhosis. J. Autoimmun.35(4), 436–442 (2010).
   PubMed Web of Science ®Google Scholar
• Oertelt S, Rieger R, Selmi C et al. A sensitive bead assay for antimitochondrial antibodies: Chipping away at AMA-negative primary biliary cirrhosis. Hepatology45(3), 659–665 (2007).
   PubMed Web of Science ®Google Scholar
• Nakamura M, Yasunami M, Kondo H et al. Analysis of HLA-DRB1 polymorphisms in Japanese patients with primary biliary cirrhosis (PBC): the HLA-DRB1polymorphism determines the relative risk of antinuclear antibodies for disease progression in PBC. Hepatol. Res.40(5), 494–504 (2010).
   PubMedGoogle Scholar
• Wiik AS, Hoier-Madsen M, Forslid J, Charles P, Meyrowitsch J. Antinuclear antibodies: a contemporary nomenclature using HEp-2 cells. J. Autoimmun.35(3), 276–290 (2010).
   PubMed Web of Science ®Google Scholar